Dogan Nesrin, King Stephanie, Emami Bahman, Mohideen Najeeb, Mirkovic Nena, Leybovich Leonid B, Sethi Anil
Department of Radiation Oncology, Loyola University Chicago Medical Center, Maywood, IL 60153, USA.
Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1480-91. doi: 10.1016/s0360-3016(03)01569-4.
Because of biologic, medical, and sometimes logistic reasons, patients may be treated with 3D conformal therapy or intensity-modulated radiation therapy (IMRT) for the initial treatment volume (PTV(1)) followed by a sequential IMRT boost dose delivered to the boost volume (PTV(2)). In some patients, both PTV(1) and PTV(2) may be simultaneously treated by IMRT (simultaneous integrated boost technique). The purpose of this work was to assess the sequential and simultaneous integrated boost IMRT delivery techniques on target coverage and normal-tissue sparing.
Fifteen patients with head-and-neck (H&N), lung, and prostate cancer were selected for this comparative study. Each site included 5 patients. In all patients, the target consisted of PTV(1) and PTV(2). The prescription doses to PTV(1) and PTV(2) were 46 Gy and 66 Gy (H&N cases), 45 Gy and 66.6 Gy (lung cases), 50 Gy and 78 Gy (prostate cases), respectively. The critical structures included the following: spinal cord, parotid glands, and brainstem (H&N structures); spinal cord, esophagus, lungs, and heart (lung structures); and bladder, rectum, femurs (prostate structures). For all cases, three IMRT plans were created: (1) 3D conformal therapy to PTV(1) followed by sequential IMRT boost to PTV(2) (sequential-IMRT(1)), (2) IMRT to PTV(1) followed by sequential IMRT boost to PTV(2) (sequential-IMRT(2)), and (3) Simultaneous integrated IMRT boost to both PTV(1) and PTV(2) (SIB-IMRT). The treatment plans were compared in terms of their dose-volume histograms, target volume covered by 100% of the prescription dose (D(100%)), and maximum and mean structure doses (D(max) and D(mean)).
H&N cases: SIB-IMRT produced better sparing of both parotids than sequential-IMRT(1), although sequential-IMRT(2) also provided adequate parotid sparing. On average, the mean cord dose for sequential-IMRT(1) was 29 Gy. The mean cord dose was reduced to approximately 20 Gy with both sequential-IMRT(2) and SIB-IMRT. Prostate cases: The volume of rectum receiving 70 Gy or more (V(>70 Gy)) was reduced to 18.6 Gy with SIB-IMRT from 22.2 Gy with sequential-IMRT(2). SIB-IMRT reduced the mean doses to both bladder and rectum by approximately 10% and approximately 7%, respectively, as compared to sequential-IMRT(2). The mean left and right femur doses with SIB-IMRT were approximately 32% lower than obtained with sequential-IMRT(1). Lung cases: The mean heart dose was reduced by approximately 33% with SIB-IMRT as compared to sequential-IMRT(1). The mean esophagus dose was also reduced by approximately 10% using SIB-IMRT as compared to sequential-IMRT(1). The percentage of the lung volume receiving 20 Gy (V(20 Gy)) was reduced to 26% by SIB-IMRT from 30.6% with sequential-IMRT(1).
For equal PTV coverage, both sequential-IMRT techniques demonstrated moderately improved sparing of the critical structures. SIB-IMRT, however, markedly reduced doses to the critical structures for most of the cases considered in this study. The conformality of the SIB-IMRT plans was also much superior to that obtained with both sequential-IMRT techniques. The improved conformality gained with SIB-IMRT may suggest that the dose to nontarget tissues will be lower.
由于生物学、医学以及有时是后勤方面的原因,患者可能先接受三维适形放疗或调强放射治疗(IMRT)来治疗初始治疗体积(PTV(1)),随后对加量体积(PTV(2))进行序贯IMRT加量。在一些患者中,PTV(1)和PTV(2)可同时接受IMRT治疗(同步整合加量技术)。本研究的目的是评估序贯和同步整合加量IMRT技术在靶区覆盖和正常组织保护方面的效果。
选取15例头颈部(H&N)、肺部和前列腺癌患者进行此项对比研究。每个部位包括5例患者。所有患者的靶区均由PTV(1)和PTV(2)组成。PTV(1)和PTV(2)的处方剂量分别为46 Gy和66 Gy(H&N病例)、45 Gy和66.6 Gy(肺部病例)、50 Gy和78 Gy(前列腺病例)。关键结构包括:脊髓、腮腺和脑干(H&N结构);脊髓、食管、肺和心脏(肺部结构);膀胱、直肠、股骨(前列腺结构)。对于所有病例,创建了三个IMRT计划:(1)对PTV(1)进行三维适形放疗,随后对PTV(2)进行序贯IMRT加量(序贯IMRT(1)),(2)对PTV(1)进行IMRT,随后对PTV(2)进行序贯IMRT加量(序贯IMRT(2)),以及(3)对PTV(1)和PTV(2)同时进行同步整合IMRT加量(SIB-IMRT)。根据剂量体积直方图、100%处方剂量覆盖的靶区体积(D(100%))以及最大和平均结构剂量(D(max)和D(mean))对治疗计划进行比较。
H&N病例:与序贯IMRT(1)相比,SIB-IMRT对双侧腮腺的保护更好,尽管序贯IMRT(2)也能提供足够的腮腺保护。平均而言,序贯IMRT(1)的脊髓平均剂量为29 Gy。序贯IMRT(2)和SIB-IMRT的脊髓平均剂量均降至约20 Gy。前列腺病例:接受70 Gy及以上剂量的直肠体积(V(>70 Gy)),SIB-IMRT使其从序贯IMRT(2)的22.2 Gy降至18.6 Gy。与序贯IMRT(2)相比,SIB-IMRT使膀胱和直肠的平均剂量分别降低了约10%和约7%。SIB-IMRT时左、右股骨的平均剂量比序贯IMRT(1)时低约32%。肺部病例:与序贯IMRT(1)相比,SIB-IMRT使心脏平均剂量降低了约33%。与序贯IMRT(1)相比,使用SIB-IMRT时食管平均剂量也降低了约10%。接受20 Gy剂量的肺体积百分比(V(20 Gy)),SIB-IMRT使其从序贯IMRT(1)的30.6%降至26%。
对于相同的PTV覆盖情况,两种序贯IMRT技术在关键结构保护方面均有适度改善。然而,在本研究考虑的大多数病例中,SIB-IMRT显著降低了关键结构的剂量。SIB-IMRT计划的适形性也明显优于两种序贯IMRT技术。SIB-IMRT获得的更好适形性可能意味着非靶组织的剂量会更低。